カテゴリー： 世界, 医療/バイオ, visiongain

世界の希少疾患市場（2023-2033)：疾患別（がん、代謝疾患、神経疾患、血液疾患、感染症、筋骨格障害、心血管疾患、その他）、種類別（非生物製剤、生物製剤）、エンドユーザー別（専門薬局、病院薬局、小売薬局）、年齢別（大人、子供）、地域別

【英語タイトル】Rare Diseases Market Report 2023-2033 : Forecasts by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Haematological Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), by Type (Non-biologics, Biologics), by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), by Age (Adult, Paediatric) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

visiongainが出版した調査資料（VGA23MA025）・商品コード：VGA23MA025
・発行会社（調査会社）：visiongain
・発行日：2023年2月28日
・ページ数：290
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Sigle User（1名様閲覧用、1年間、印刷不可）GBP3,950 ⇒換算￥750,500見積依頼/購入/質問フォーム
Enterprise（法人閲覧用、1年間、印刷可）GBP6,950 ⇒換算￥1,320,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Visiongain社の本調査レポートでは、世界の希少疾患市場規模が、2033年まで年平均成長率12.27%で拡大すると予想しています。本レポートは、希少疾患の世界市場を調査対象とし、レポート概要、エグゼクティブサマリー、市場動向、疾患別（がん、代謝疾患、神経疾患、血液疾患、その他）分析、種類別（非生物製剤、生物製剤）分析、エンドユーザー別（専門薬局、病院薬局、小売薬局）分析、年齢別（大人、子供）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ、アメリカ、カナダ、ドイツ、イギリス、フランス、イタリア、スペイン、ロシア、日本、中国、インド、オーストラリア、韓国、ブラジル、メキシコ、中東、南アフリカ、その他地域）分析、企業情報などの項目を掲載しています。また、本レポートには、AbbVie Inc.、Alexion Pharmaceuticals, Inc. (AstraZeneca)、Amgen Inc.、Biogen Inc.、Bristol-Myers Squibb Company、F. Hoffmann-La Roche Ltd.などの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・市場動向
・世界の希少疾患市場規模：疾患別
- がんの市場規模
- 代謝疾患の市場規模
- 神経疾患の市場規模
- 血液疾患の市場規模
- その他疾患の市場規模
・世界の希少疾患市場規模：種類別
- 非生物製剤の市場規模
- 生物製剤の市場規模
・世界の希少疾患市場規模：エンドユーザー別
- 専門薬局における市場規模
- 病院薬局における市場規模
- 小売薬局における市場規模
・世界の希少疾患市場規模：年齢別
- 大人における市場規模
- 子供における市場規模
・世界の希少疾患市場規模：地域別
- 北米の希少疾患市場規模
アメリカの希少疾患市場規模
カナダの希少疾患市場規模
- ヨーロッパの希少疾患市場規模
ドイツの希少疾患市場規模
イギリスの希少疾患市場規模
フランスの希少疾患市場規模
イタリアの希少疾患市場規模
スペインの希少疾患市場規模
ロシアの希少疾患市場規模
- アジア太平洋の希少疾患市場規模
日本の希少疾患市場規模
中国の希少疾患市場規模
インドの希少疾患市場規模
オーストラリアの希少疾患市場規模
韓国の希少疾患市場規模
- 中南米の希少疾患市場規模
ブラジルの希少疾患市場規模
メキシコの希少疾患市場規模
- 中東・アフリカの希少疾患市場規模
中東の希少疾患市場規模
南アフリカの希少疾患市場規模
- その他地域の希少疾患市場規模
・企業情報

The Rare Diseases Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Home-based Care Anticipated to Offer Lucrative Growth Prospects
There are unmet requirements for elderly, frail people with multiple diseases, but many support services today focus on patients with rare or ultra-rare diseases. In addition, there are numerous chronic conditions present in sizable patient communities, even in younger age groups. Expanding home-based healthcare services could therefore have positive effects on bigger patient populations and health systems.

Due to the high degrees of medical complexity, managing comorbidities and multi-morbidities is especially difficult. A patient with heart failure who also requires infusion therapy for cancer poses a problem with timing the administration of the diuretics because the patient must travel to the infusion facility. Home-based care services may develop into a potent catalyst for raising standards of care, enhancing patient satisfaction, and cutting expenses. While there are obvious and distinct benefits for patients and carers with complex and rare diseases, there are also advantages for larger patient populations with more widespread conditions who may face difficulties due to the complexity of their therapy or the effects of comorbidities and multidisease.

What Questions Should You Ask before Buying a Market Research Report?
• How is the rare diseases market evolving?
• What is driving and restraining the rare diseases market?
• How will each rare diseases submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each rare diseases submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading rare diseases markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the rare diseases projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
rare diseases projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the rare diseases market?
• Where is the rare diseases market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the rare diseases market today, and over the next 10 years:
• Our 290-page report provides 107 tables and 186 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the rare diseases market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Diseases
• Cancer
• Metabolic Diseases
• Neurological Conditions
• Hematologic Disorders
• Infectious Diseases
• Musculoskeletal Disorders
• Cardiovascular Disorders
• Others

Type
• Non-biologics
• Biologics

End-users
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Age
• Adult
• Paediatric

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Rare Diseases Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie Inc.
• Alexion Pharmaceuticals, Inc. (AstraZeneca)
• Amgen Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Merck & Co Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceuticals
• Teva Pharmaceuticals

Overall world revenue for Rare Diseases Market, 2023 to 2033 in terms of value the market will surpass US$205.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Rare Diseases Market, 2023 to 2033 report help you?
In summary, our 290-page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Rare Diseases Market, 2023 to 2033 Market, with forecasts for diseases, type, end-users, and age, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 21 key national markets – See forecasts for the Rare Diseases Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the Rare Diseases Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Rare Diseases Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Rare Diseases Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Number of Approval Driving Market Growth
3.2.1.2 Robust Pipeline by Major Players
3.2.1.2.1 Pfizer Rare Disease Pipeline
3.2.1.2.2 Sanofi Genzyme Corporation Rare Disease Pipeline
3.2.1.2.3 Novo Nordisk Rare Disease Pipeline
3.2.1.3 Increasing Awareness
3.2.2 Market Restraining Factors
3.2.2.1 High Research and Development Costs
3.2.2.2 High Entry Barriers to Challenge Market Growth
3.2.2.3 Physical Management of Patients Likely to Challenge Market Growth
3.2.3 Market Opportunities
3.2.3.1 Increasing Demand from Emerging Economies
3.2.3.2 Home-based Care Anticipated to Offer Lucrative Growth Prospects
3.2.3.3 Increasing Government Support
3.2.3.4 Rare Diseases Clinical Activity by Indication
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Buyers (Low)
3.4.2 Bargaining Power of Suppliers (medium)
3.4.3 Threat of Substitutes (Low)
3.4.4 Threat of New Entrants (Low)
3.4.5 Industry Rivalry (High)

4 Rare Diseases Market Analysis by Diseases
4.1 Key Findings
4.2 Diseases Segment: Market Attractiveness Index
4.3 Rare Diseases Market Size Estimation and Forecast by Diseases
4.4 Cancer
4.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Metabolic Diseases
4.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Neurological Conditions
4.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Hematologic Disorders
4.7.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Infectious Diseases
4.8.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.8.2 Market Share by Region, 2023 & 2033 (%)
4.9 Musculoskeletal Disorders
4.9.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.9.2 Market Share by Region, 2023 & 2033 (%)
4.10 Cardiovascular Disorders
4.10.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.10.2 Market Share by Region, 2023 & 2033 (%)
4.11 Others
4.11.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.11.2 Market Share by Region, 2023 & 2033 (%)

5 Rare Diseases Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Rare Diseases Market Size Estimation and Forecast by Type
5.4 Non-biologics
5.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Biologics
5.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
5.5.2 Market Share by Region, 2023 & 2033 (%)

6 Rare Diseases Market Analysis by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Rare Diseases Market Size Estimation and Forecast by End-users
6.4 Specialty Pharmacies
6.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Hospital Pharmacies
6.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Retail Pharmacies
6.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Rare Diseases Market Analysis by Age
7.1 Key Findings
7.2 Age Segment: Market Attractiveness Index
7.3 Rare Diseases Market Size Estimation and Forecast by Age
7.4 Adult
7.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 Pediatric
7.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.5.2 Market Share by Region, 2023 & 2033 (%)

8 Rare Diseases Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Rare Diseases Market Analysis
9.1 Key Findings
9.2 North America Rare Diseases Market Attractiveness Index
9.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
9.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
9.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
9.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
9.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
9.9 U.S. Rare Diseases Market Analysis
9.10 Canada Rare Diseases Market Analysis

10 Europe Rare Diseases Market Analysis
10.1 Key Findings
10.2 Europe Rare Diseases Market Attractiveness Index
10.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
10.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
10.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
10.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
10.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
10.9 Germany Rare Diseases Market Analysis
10.10 UK Rare Diseases Market Analysis
10.11 France Rare Diseases Market Analysis
10.12 Italy Rare Diseases Market Analysis
10.13 Spain Rare Diseases Market Analysis
10.14 Russia Rare Diseases Market Analysis
10.15 Rest of Europe Rare Diseases Market Analysis

11 Asia Pacific Rare Diseases Market Analysis
11.1 Key Findings
11.2 Asia Pacific Rare Diseases Market Attractiveness Index
11.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
11.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
11.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
11.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
11.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
11.9 Japan Rare Diseases Market Analysis
11.10 China Rare Diseases Market Analysis
11.11 India Rare Diseases Market Analysis
11.12 Australia Rare Diseases Market Analysis
11.13 South Korea Rare Diseases Market Analysis
11.14 Rest of Asia Pacific Rare Diseases Market Analysis

12 Latin America Rare Diseases Market Analysis
12.1 Key Findings
12.2 Latin America Rare Diseases Market Attractiveness Index
12.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
12.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
12.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
12.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
12.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
12.9 Brazil Rare Diseases Market Analysis
12.10 Mexico Rare Diseases Market Analysis
12.11 Rest of Latin America Rare Diseases Market Analysis

13 MEA Rare Diseases Market Analysis
13.1 Key Findings
13.2 MEA Rare Diseases Market Attractiveness Index
13.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
13.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
13.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
13.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
13.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
13.9 GCC Rare Diseases Market Analysis
13.10 South Africa Rare Diseases Market Analysis
13.11 Rest of MEA Rare Diseases Market Analysis

14 Company Profiles
14.1 AbbVie Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.3.1 Net Revenue, 2015-2022
14.1.3.2 Regional Market Shares, 2021
14.1.3.3 Gross Profit, 2015-2022
14.1.3.4 R&D, 2015-2022
14.1.4 Product Benchmarking
14.2 Alexion Pharmaceuticals, Inc. (AstraZeneca)
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.2.4 Strategic Outlook
14.3 Amgen Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2022
14.3.3.2 Regional Market Shares, 2022
14.3.3.3 Gross Profit, 2015-2022
14.3.3.4 R&D, 2015-2022
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Biogen Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2015-2021
14.4.3.2 Gross Profit, 2015-2021
14.4.3.3 R&D, 2015-2021
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 F. Hoffmann-La Roche Ltd.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2015-2021
14.5.3.2 Gross Profit, 2015-2021
14.5.3.3 R&D, 2015-2021
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Johnson & Johnson Services, Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2015-2022
14.6.3.2 Regional Market Shares, 2021
14.6.3.3 Gross Profit, 2015-2022
14.6.3.4 R&D, 2015-2022
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Merck & Co Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2015-2022
14.7.3.2 Regional Market Shares, 2021
14.7.3.3 Gross Profit, 2015-2022
14.7.3.4 R&D, 2015-2022
14.7.4 Product Benchmarking
14.8 Novartis AG
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2015-2022
14.8.3.2 Regional Market Shares, 2021
14.8.3.3 Gross Profit, 2015-2022
14.8.3.4 R&D, 2015-2022
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Pfizer Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2015-2022
14.9.3.2 Regional Market Shares, 2021
14.9.3.3 Gross Profit, 2015-2022
14.9.3.4 R&D, 2015-2022
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Sanofi S.A.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2015-2022
14.10.3.2 Regional Market Shares, 2021
14.10.3.3 Gross Profit, 2015-2022
14.10.3.4 R&D, 2015-2022
14.10.4 Product Benchmarking
14.11 Takeda Pharmaceuticals
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2015-2022
14.11.3.2 Gross Profit, 2015-2022
14.11.3.3 R&D, 2015-2022
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Teva Pharmaceuticals
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2015-2021
14.12.3.2 Regional Market Shares, 2021
14.12.3.3 Gross Profit, 2015-2021
14.12.3.4 R&D, 2015-2021
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Bristol-Myers Squibb Company
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2015-2022
14.13.3.2 Gross Profit, 2015-2022
14.13.3.3 R&D, 2015-2022
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks
15.2 Recommendations for Market Players



★調査レポート[世界の希少疾患市場（2023-2033)：疾患別（がん、代謝疾患、神経疾患、血液疾患、感染症、筋骨格障害、心血管疾患、その他）、種類別（非生物製剤、生物製剤）、エンドユーザー別（専門薬局、病院薬局、小売薬局）、年齢別（大人、子供）、地域別] (コード：VGA23MA025)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の希少疾患市場（2023-2033)：疾患別（がん、代謝疾患、神経疾患、血液疾患、感染症、筋骨格障害、心血管疾患、その他）、種類別（非生物製剤、生物製剤）、エンドユーザー別（専門薬局、病院薬局、小売薬局）、年齢別（大人、子供）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の希少疾患治療市場2022-2029：治療領域別（がん、神経疾患、心血管疾患、筋骨格疾患、血液疾患、感染症、代謝疾患、内分泌疾患、その他）、投与経路別、薬剤種類別、流通チャネル別、地域別
  • 世界の治療的血漿交換市場2023-2031：疾患別（神経疾患、腎疾患、血液疾患、代謝疾患、その他）
  • 世界の婦人科用治療薬市場（2023-2033)：疾患別（婦人科系がん、避妊、女性不妊症、更年期障害、多嚢胞性卵巣症候群（PCOS）、その他）、治療薬別（非ホルモン治療薬、ホルモン治療薬）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、種類別（ジェネリック、ブランド）、地域別
  • 世界のオキシメトロン粉末市場2023-2030：用途別（栄養補助食品、患者ケア、パーソナルケア、疾病治療）、流通チャネル別（病院薬局、小売薬局、専門薬局）、地域別
  • 世界のマイクロRNA市場（2023-2033）：サービス別（検体、サービス種類）、製品別（装置、消耗品）、用途別（がん、感染症、免疫疾患、循環器疾患、神経疾患、その他）、エンドユーザー別（バイオ＆製薬企業、学術＆政府研究機関、その他）、地域別
  • 世界の抗血小板薬市場2023-2033：薬剤タイプ別（アスピリン、クロピドグレル、チカグレロル、プラスグレル、その他）、流通チャネル別（病院薬局、小売薬局、オンライン薬局、その他）、用途別（血管形成術、経皮的冠動脈インターベンション、その他）、エンドユーザー別、地域別
  • 世界の特許医薬品市場2023年-2032年：剤形別（固形医薬品、液体医薬品、その他）、疾患別（心血管疾患、がん、自己免疫疾患、その他）、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン薬局）
  • 世界の胸腺がん治療市場（~2033）：がん種類別（胸腺腫、胸腺がん）、治療法別（手術、放射線療法、化学療法、ホルモン療法、標的療法、免疫療法）、エンドユーザー別（病院＆クリニック、研究＆学術機関）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界のペプチド感染症治療薬市場2023-2033：治療薬別（テラプレビル、ボセプレビル）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別
  • 世界の胃がん市場2021年-2031年：疾患種類別（腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他）、治療種類別（免疫療法、標的療法、化学療法、放射線療法＆外科）、薬剤クラス別（PD-1/PD-L1阻害剤、HER2アンタゴニスト、VEGFR2アンタゴニスト、その他）、投与経路別（経口、注射剤）、流通チャネル別（病院薬局、専門薬局＆小売薬局、その他）

    • ◆H&Iグローバルリサーチのお客様（例）◆